智通财经网·2025-08-14 02:35Core Viewpoint - BeiGene (06160) shares rose over 4%, reaching 187.2 HKD with a trading volume of 341 million HKD, following the announcement of the initiation of a Phase III clinical trial for its PD-1 inhibitor, Tislelizumab, for specific cancer treatment [1] Company Summary - The Phase III clinical trial for Tislelizumab is aimed at treating locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy as first-line therapy [1] - Tislelizumab is BeiGene's core product, which has been approved in 47 markets globally [1] - Since its launch in 2019, Tislelizumab has been utilized in treating key cancer types such as urothelial carcinoma and non-small cell lung cancer, benefiting millions of patients worldwide [1] - In the first half of 2025, Tislelizumab generated sales of 2.643 billion CNY, reflecting a year-on-year growth of 20.6% [1]